Catalyst Pharmaceuticals, Inc.

Big multibillion-dollar merger-and-acquisition deals have been few and far between in 2025, but that does not mean dealmaking has come to a standstill. In fact, based on Scrip ’s interviews and obser

Rare and pediatric disease drug sponsors and the US Food and Drug Administration could resolve several ongoing rare and pediatric drug development issues in a compromise bill to fund the government th

Santhera Pharmaceuticals says that its Duchenne muscular dystrophy (DMD) treatment Agamree has got off to a strong start and while pricing negotiations are unsurprisingly proving tricky, the Swiss fi

The US Food and Drug Administration’s full approval of Sarepta Therapeutics, Inc. ’s Elevidys (delandistrogene moxeparvovec-rokl) pastes another jewel in the company’s “most contentious approvals” cr